3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Prostatic Neoplasms
9
Prostatic Neoplasms, Castration-Resistant
6
Metastatic Castration-resistant Prostate Cancer
2
Pain
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastatic Castration-resistant Prostate Cancer
1
Advanced Prostate Cancer
1
Interventions
Surveys and Questionnaires
86
Blood Specimen Collection
58
Interviews as Topic
28
Observation
15
Data Collection
15
Radiotherapy
12
Watchful Waiting
11
Magnetic Resonance Spectroscopy
11
Hematologic Tests
11
Exercise
11
Drug Therapy
11
Quality of Life
9
Biopsy
8
Specimen Handling
7
Therapeutics
6
Restraint, Physical
6
Magnetic Resonance Imaging
6
Focus Groups
6
pembrolizumab
5
Standard of Care
5
Rivaroxaban
5
Phlebotomy
5
Nivolumab
5
Lapatinib
5
Immune Checkpoint Inhibitors
5
atezolizumab
4
apixaban
4
Trastuzumab
4
Patient Reported Outcome Measures
4
Palliative Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasms
×
radium Ra 223 dichloride
×
Clear all
NCT02331303
2018-01-23
A Drug Utilization Study of Radium-223 in Sweden
Bayer
Completed
37 enrolled